FDA Pulls Plug on Rare Depression Treatment Drug
Published Date: 3/14/2025
Notice
Summary
The FDA is officially pulling the plug on ZULRESSO, a drug made by Sage Therapeutics, because Sage decided to stop selling it. This means patients and doctors won’t be able to get this medicine anymore, but no worries—this change won’t cause any sudden money surprises. The withdrawal is effective now, so everyone should plan accordingly.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
ZULRESSO approval withdrawn; no access
The FDA is withdrawing approval of ZULRESSO (brexanolone) solution, 100 mg/20 mL, because Sage Therapeutics notified the Agency that the product is no longer marketed. Patients and doctors will no longer be able to obtain this medicine, and the withdrawal is effective now. The notice also states this change will not cause any sudden money surprises.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
2026-16943, International Association of Color Manufacturers; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by the International Association of Color Manufacturers, proposing that we amend our color additive regulations to provide for the safe use of acetone as a solvent in the manufacture of carrot oil. The petition also proposes to add heavy metal limits and secondary names for carrot oil. FDA may also consider other changes to the regulation, as appropriate, during the course of our review.
Previous / Next Documents
Previous: 2025-04100, Proposed Extension of Information Collection Request Submitted for Public Comment; Comment Request for Form 14411
The IRS wants to keep collecting info using Form 14411, which helps people report big tax problems. They’re asking the public and other agencies to share thoughts on how to make this process easier and less time-consuming. No big changes or costs are planned, but your feedback can help shape the future!
Next: 2025-04106, Bausch & Lomb Incorporated, et al.; Withdrawal of Approval of Eight Abbreviated New Drug Applications
The FDA is officially pulling the plug on eight drug approvals because the companies, including Bausch & Lomb, told them these medicines aren’t being sold anymore. This means those drugs won’t be available, but no one’s losing money since the companies asked for this. If you used these meds, it’s time to check with your doctor for alternatives!